Corneal Thinning During Topical Bevacizumab Therapy

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00515684

Enrollment

Registered

2007-08-14

Start date

2007-05-31

Completion date

2008-12-31

Last updated

2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Neovascularization

Brief summary

The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Interventions

DRUGbevacizumab (Avastin)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* clinical diagnosis of corneal neovascularization * must be able to apply eyedrop

Exclusion criteria

* have active keratitis

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026